Mode
Text Size
Log in / Sign up

Oncology

1582 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Apixaban reduces VTE risk across multiple chemotherapy regimens in ambulatory cancer patients
Oncology RCT
Apixaban reduces VTE risk across multiple chemotherapy regimens in ambulatory cancer patients Apixaban reduces blood clot risk for patients starting chemotherapy
This post hoc analysis of a randomized, double-blind, placebo-controlled trial of 563 ambulatory cancer patients found that apixaban (2.5 mg…
A new analysis shows that the blood thinner apixaban significantly lowers the risk of dangerous blood clots in cancer patients starting chem…
Education program shows 51% vs. 32% improvement in early breast cancer FACT-B scores
Oncology RCT
Education program shows 51% vs. 32% improvement in early breast cancer FACT-B scores Education Programs May Improve Early Quality of Life for Breast Cancer
This randomized controlled trial secondary analysis of 342 patients with stage 0-III breast cancer found that an education program led to gr…
A study of 342 breast cancer patients found that an education program led to faster early improvements in quality of life scores.
CEUS Differentiates FNH From HCA With 84.9% Sensitivity and 0.90 AUC
Oncology Meta-analysis
CEUS Differentiates FNH From HCA With 84.9% Sensitivity and 0.90 AUC Ultrasound helps doctors tell two liver growths apart
This meta-analysis pooled data from 228 focal nodular hyperplasias and 155 hepatocellular adenomas to assess contrast-enhanced ultrasound fo…
A new look at ultrasound imaging shows it can help doctors tell the difference between two common types of liver growths.
CLEC10A marks an MHC class II-high myeloid state in neuroblastoma with survival associations in non-amplified cases
Oncology Meta-analysis
CLEC10A marks an MHC class II-high myeloid state in neuroblastoma with survival associations in non-amplified cases CLEC10A Expression Linked to Survival in Certain Neuroblastoma Cases
This meta-analysis evaluates the role of CLEC10A expression in neuroblastoma across 920 tumors. The analysis identifies CLEC10A as a marker …
New research identifies a specific protein marker, CLEC10A, that may link to better survival outcomes in some patients with neuroblastoma.
N-acetylcysteine, glutathione, and vitamin E may reduce severe chemotherapy-induced peripheral neuropathy
Oncology Sys. Review
N-acetylcysteine, glutathione, and vitamin E may reduce severe chemotherapy-induced peripheral neuropathy Antioxidant Supplements May Lower Severe Nerve Damage From Chemotherapy
This meta-analysis of 1625 patients evaluated the efficacy of glutathione, N-acetylcysteine, and vitamin E in preventing chemotherapy-induce…
A review of 1,625 patients found N-acetylcysteine, glutathione, and vitamin E may cut severe chemotherapy nerve damage, but evidence is earl…
Local ablative treatment reduces progression risk and improves survival in NSCLC patients with oligoprogression
Oncology Meta-analysis
Local ablative treatment reduces progression risk and improves survival in NSCLC patients with oligoprogression Local Treatment May Help Lung Cancer Patients on Immunotherapy
This meta-analysis of 22 studies indicates that local ablative treatment (LAT) for oligoprogression during anti-PD-1 or anti-PD-L1 therapy i…
Adding local radiation to immunotherapy may help patients with lung cancer whose tumors start to grow in specific areas.
Teclistamab and glofitamab carry higher non-relapse mortality signals than mosunetuzumab in BsAb meta-analysis
Oncology Meta-analysis
Teclistamab and glofitamab carry higher non-relapse mortality signals than mosunetuzumab in BsAb meta-analysis New data reveals safety risks for certain lymphoma and myeloma drugs
This meta-analysis combined a systematic review and meta-analysis with FAERS pharmacovigilance data to estimate non-relapse mortality (NRM) …
New data highlights different safety risks and side effects for three specific drugs used to treat certain types of blood cancers.
Bone metastasis and anxiety significantly increase the risk of pain crises in cancer patients
Oncology Meta-analysis
Bone metastasis and anxiety significantly increase the risk of pain crises in cancer patients Factors that predict pain crises in cancer patients
This meta-analysis of 1865 cancer patients identifies a 37% pooled incidence of pain crisis. The analysis identifies bone metastasis, radiot…
New data identifies how bone metastasis, certain treatments, and mental health factors like anxiety can predict pain crises in cancer patien…
Fertility treatments are associated with a modestly elevated risk of melanoma in women
Oncology Meta-analysis
Fertility treatments are associated with a modestly elevated risk of melanoma in women Fertility Treatments Linked to Slightly Higher Melanoma Risk
This meta-analysis of observational studies involving 3,733,499 women indicates that fertility treatments are associated with a modestly ele…
A large study of over 3 million women found a modest link between certain fertility treatments and melanoma risk.
BRAF-directed regimens linked to 22.3-month median OS in BRAF-mutant mCRC
Oncology Meta-analysis
BRAF-directed regimens linked to 22.3-month median OS in BRAF-mutant mCRC Comparing Different Targeted Treatments for Patients with BRAF Mutant Colorectal Cancer
This reconstructed individual patient data meta-analysis pooled 18 randomized trials (11,931 patients) to compare targeted therapy classes i…
New data shows that treatments targeting the BRAF mutation offer a longer life expectancy than other targeted therapies.
ANXA1 dominance independently predicts recurrence in colorectal cancer (HR 1.43)
Oncology RCT
ANXA1 dominance independently predicts recurrence in colorectal cancer (HR 1.43) New Biomarkers Help Doctors Predict Outcomes for Patients with Colorectal Cancer
This translational biomarker substudy of the randomized SCOT trial analyzed tissue microarrays from 2163 patients with colorectal cancer. AN…
Doctors are using two specific markers to better predict how colorectal cancer will behave and help patients survive longer.
Lower SLC25A28 expression linked to shorter survival in glioma, pooled HR 1.91
Oncology Meta-analysis
Lower SLC25A28 expression linked to shorter survival in glioma, pooled HR 1.91 Low SLC25A28 Linked to Shorter Survival in Glioma
This meta-analysis with bioinformatic and in vitro analyses examined SLC25A28 expression as a prognostic marker in glioma. Lower expression …
A gene called SLC25A28 may help predict survival in glioma, but the evidence is early and not ready for routine use.